Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India

(2015) André M Siqueira et al.   BMC Medicine

Mortality attributable to Plasmodium vivaxmalaria: a clinical audit from Papua, Indonesia

(2014) Nicholas M Douglas et al.   BMC Medicine

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine

(2014) Michael T White et al.   BMC Medicine

RTS,S Vaccination Is Associated With Serologic Evidence of Decreased Exposure toPlasmodium falciparumLiver- and Blood-Stage Parasites

(2014) Joe J. Campo et al.   MOLECULAR & CELLULAR PROTEOMICS

Protective Efficacy of a Plasmodium vivax Circumsporozoite Protein-Based Vaccine in Aotus nancymaae Is Associated with Antibodies to the Repeat Region

(2014) Anjali Yadava et al.   PLoS Neglected Tropical Diseases

Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria

(2013) Jason W. Bennett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques

(2013) Yannick Vanloubbeeck et al.   VACCINE

A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010

(2012) Peter W. Gething et al.   PLoS Neglected Tropical Diseases

Consistent Safety and Infectivity in Sporozoite Challenge Model of Plasmodium vivax in Malaria-Naive Human Volunteers

(2011) Sócrates Herrera et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

(2011) Ally Olotu et al.   LANCET INFECTIOUS DISEASES

Determinants of relapse periodicity in Plasmodium vivax malaria

(2011) Nicholas J White   MALARIA JOURNAL

From the circumsporozoite protein to the RTS,S/AS candidate vaccine

(2010) Joe Cohen et al.   Human vaccines & immunotherapeutics

Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination

(2010) Timothy N.C. Wells et al.   TRENDS IN PARASITOLOGY

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

(2009) Michele D. Spring et al.   PLoS One

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

(2009) Mark E. Polhemus et al.   PLoS One

The pathophysiology of vivax malaria

(2009) Nicholas M. Anstey et al.   TRENDS IN PARASITOLOGY

Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax

(2009) Brian A. Bell et al.   VACCINE